Back to Search
ANDREW TENENBAUM, DO
DO
Pediatrics Physician
NPI: 1811933252Individual
Specialties, Licenses & Credentials
Pediatrics PhysicianPrimary
Pediatrics
Code: 208000000X
1932(ME)
Research & Publications (20)
Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?
PMID 18565233·Cardiovasc Diabetol·2008
8-other
Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
PMID 18230960·Adv Cardiol·2008
6-review
Insulin resistance is associated with increased risk of major cardiovascular events in patients with preexisting coronary artery disease.
PMID 17383294·Am Heart J·2007
8-other
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
PMID 17002798·Cardiovasc Diabetol·2006
6-review
Long-term versus intermediate-term supervised exercise training in advanced heart failure: effects on exercise tolerance and mortality.
PMID 16707174·Int J Cardiol·2006
4-observational
Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.
PMID 16606809·Arch Intern Med·2006
8-other
Smoking and development of type 2 diabetes in patients with decreased functional capacity.
PMID 16186056·Int J Cardiol·2005
4-observational
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
PMID 16168052·Cardiovasc Diabetol·2005
6-review
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.
PMID 15911729·Arch Intern Med·2005
3-trial
Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.
PMID 15872029·Eur Heart J·2005
4-observational
Macrovascular complications of metabolic syndrome: an early intervention is imperative.
PMID 15458679·Int J Cardiol·2004
6-review
Impaired glucose metabolism in patients with heart failure: pathophysiology and possible treatment strategies.
PMID 15449970·Am J Cardiovasc Drugs·2004
6-review
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
PMID 15123532·Circulation·2004
3-trial
Aortic valve calcification in hypertensive patients: prevalence, risk factors and association with transvalvular flow velocity.
PMID 14996468·Int J Cardiol·2004
8-other
Functional capacity impairment in patients with coronary artery disease: prevalence, risk factors and prognosis.
PMID 14713732·Cardiology·2003
8-other
Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus.
PMID 14633284·Cardiovasc Diabetol·2003
8-other
Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR).
PMID 12834541·Cardiovasc Diabetol·2003
8-other
Functional class in patients with heart failure is associated with the development of diabetes.
PMID 12681453·Am J Med·2003
4-observational
Does participation in a long-term clinical trial lead to survival gain for patients with coronary artery disease?
PMID 12015246·Am J Med·2002
8-other
Combined coronary and mitral annulus calcium detection in the non-invasive diagnosis of coronary artery disease in patients with systemic hypertension.
PMID 12004263·Coron Artery Dis·2002
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 100 FODEN RD, WEST, SITE 303
SOUTH PORTLAND, ME 04106 - Phone
- (207) 523-3767
Quick Facts
- NPI
- 1811933252
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile